Vbl_Logo.png
VBL Therapeutics to Report Third Quarter Financial Results on November 15
08 nov. 2021 08h00 HE | VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant...
Logo.jpg
VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
26 mars 2020 07h54 HE | Vascular Biogenics Ltd.
OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion, of an absolute percentage advantage of 10%...
VBL2021Logo_Dark.jpg
VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18
09 nov. 2017 08h00 HE | VBL Therapeutics
TEL AVIV, Israel, Nov. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...